Converging Roles of Neuroinflammation, Mitochondrial Injury, Protein Misfolding, Oxidative Stress, and Synaptic Dysfunction in Schizophrenia and Parkinson’s Disease: Translational Perspectives for Multi-Target Drug Development

Schizophrenia (SCZ) and Parkinson’s disease (PD) are among the most debilitating neurological and neuropsychiatric disorders worldwide, contributing substantially to global disability, healthcare burden, and socioeconomic loss. Although schizophrenia has traditionally been classified as a psychiatric disorder and Parkinson’s disease as a neurodegenerative movement disorder, emerging evidence suggests that both conditions share several overlapping molecular and cellular mechanisms including neuroinflammation, oxidative stress, mitochondrial dysfunction, protein misfolding, and synaptic abnormalities (Kahn et al., 2015; Poewe et al., 2017). These converging mechanisms have generated increasing interest in identifying common therapeutic targets capable of addressing multiple pathological pathways simultaneously.

Schizophrenia affects approximately 24 million individuals globally and is characterized by chronic disturbances in perception, cognition, behavior, and emotional regulation (World Health Organization [WHO], 2022). The disorder usually manifests during late adolescence or early adulthood and significantly impairs occupational and social functioning. Clinically, schizophrenia symptoms are broadly categorized into positive symptoms such as hallucinations, delusions, and disorganized thinking; negative symptoms including social withdrawal, anhedonia, and blunted affect; and cognitive impairments involving deficits in attention, executive function, and working memory (McCutcheon et al., 2020). Despite decades of research, the precise etiology of schizophrenia remains unclear and is considered multifactorial, involving genetic predisposition, environmental stressors, neurodevelopmental abnormalities, and immune dysregulation.

The neurochemical basis of schizophrenia has primarily centered around the dopamine hypothesis, which proposes hyperactivity of dopaminergic transmission in mesolimbic pathways and hypoactivity in mesocortical circuits (Howes & Kapur, 2009). However, dopamine dysregulation alone cannot fully explain the broad clinical manifestations of the disease. Consequently, additional hypotheses involving glutamatergic and GABAergic dysfunction have gained prominence. NMDA receptor hypofunction has been strongly implicated in cognitive deficits and negative symptoms, while impaired GABAergic interneuron activity contributes to disrupted cortical synchronization and altered neuronal connectivity (Uno & Coyle, 2019). Increasingly, studies have also demonstrated the role of inflammatory cytokines, oxidative stress markers, and mitochondrial abnormalities in the pathophysiology of schizophrenia, suggesting that the disorder may involve progressive neurobiological alterations rather than being solely a neurotransmitter imbalance disorder.

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and affects nearly 10 million people worldwide (Poewe et al., 2017). The incidence of PD increases with aging, making it a major public health concern in aging populations. The disease is primarily characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine depletion within the basal ganglia circuitry. Clinically, Parkinson’s disease manifests with cardinal motor symptoms including resting tremor, bradykinesia, muscular rigidity, and postural instability. However, non-motor manifestations such as depression, anxiety, sleep disturbances, cognitive impairment, autonomic dysfunction, and psychosis are increasingly recognized as major contributors to disease burden and reduced quality of life (Schapira et al., 2017).

The pathological hallmark of PD is the intracellular accumulation of misfolded α-synuclein protein aggregates forming Lewy bodies, which contribute to neuronal dysfunction and degeneration (Spillantini et al., 1997). In addition to protein aggregation, mitochondrial dysfunction plays a critical role in PD progression, particularly impairment of mitochondrial complex I activity and defective mitophagy pathways involving PINK1 and Parkin proteins (Exner et al., 2012). Oxidative stress generated through dopamine metabolism, iron accumulation, and mitochondrial ROS production further accelerates neuronal injury. Simultaneously, activated microglia and elevated pro-inflammatory cytokines contribute to chronic neuroinflammation, thereby amplifying neurodegenerative processes (Hirsch & Hunot, 2009).

Recent evidence indicates significant overlap between schizophrenia and Parkinson’s disease at neuropathological and molecular levels. Synaptic dysfunction is increasingly recognized as a common denominator in both disorders, affecting neurotransmission, neural plasticity, and neuronal connectivity (Grant, 2012). Abnormal synaptic pruning mediated by microglial activation has been implicated in schizophrenia, while synaptic degeneration and impaired neurotransmitter release are central to Parkinsonian pathology. Furthermore, both disorders exhibit dysregulation of dopaminergic signaling, mitochondrial energy metabolism, and neuroimmune responses. Notably, cognitive deficits and psychiatric manifestations such as hallucinations, depression, and psychosis frequently occur in Parkinson’s disease, further highlighting the overlap between neurodegenerative and psychiatric mechanisms (Weintraub & Burn, 2011).

Neuroinflammation has emerged as a major converging pathway in both disorders. Elevated levels of inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) have been reported in patients with schizophrenia and Parkinson’s disease (Miller & Goldsmith, 2017). Chronic activation of microglia contributes to excessive oxidative stress, neuronal damage, and altered synaptic remodeling. Similarly, mitochondrial dysfunction and oxidative stress create a vicious cycle in which reactive oxygen species further activate inflammatory pathways and promote protein misfolding. These interconnected pathological processes suggest that schizophrenia and Parkinson’s disease should not be viewed as isolated disorders but rather as part of a broader spectrum of neuroprogressive diseases sharing common biological disturbances.

Current therapeutic strategies for schizophrenia and Parkinson’s disease remain largely symptomatic and fail to adequately halt disease progression. Antipsychotic medications primarily target dopamine receptors but are associated with substantial adverse effects including extrapyramidal symptoms and metabolic disturbances (Correll et al., 2015). Likewise, levodopa-based therapies for Parkinson’s disease improve motor symptoms but lose efficacy over time and do not prevent neuronal degeneration. The complexity and multifactorial nature of these disorders have highlighted the limitations of single-target pharmacological approaches.

Consequently, there is growing interest in multi-target therapeutic strategies capable of simultaneously modulating oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic abnormalities. Advances in systems biology, network pharmacology, artificial intelligence-assisted drug discovery, and nanomedicine have facilitated the identification of interconnected molecular targets and synergistic therapeutic combinations (Hopkins, 2008). Multi-target-directed ligands, phytopharmaceuticals, and nanoformulations are increasingly being explored as promising approaches for addressing the complex pathogenesis of neurodegenerative and psychiatric disorders. Comparative analysis of shared mechanisms between schizophrenia and Parkinson’s disease may therefore provide important translational insights for the development of disease-modifying therapeutics capable of improving both neurological and psychiatric outcomes.

2. Neuroinflammation as a Central Pathogenic Driver

Neuroinflammation has emerged as one of the most critical pathological mechanisms underlying both schizophrenia (SCZ) and Parkinson’s disease (PD). Traditionally considered secondary to neuronal injury, neuroinflammation is now recognized as an active contributor to disease initiation, progression, and symptom severity. Persistent activation of innate immune responses within the central nervous system (CNS) contributes to neuronal dysfunction, synaptic abnormalities, oxidative damage, and neurodegeneration through a complex network of inflammatory mediators and immune signaling pathways (Glass et al., 2010). Increasing evidence suggests that chronic inflammatory processes form a mechanistic bridge between psychiatric and neurodegenerative disorders, thereby supporting the concept of shared pathogenic pathways in SCZ and PD.

The central mediators of neuroinflammation are microglia and astrocytes, which are activated in response to neuronal stress, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), environmental toxins, and protein aggregates. Microglia are the resident immune cells of the CNS and play essential roles in synaptic remodeling, phagocytosis, and immune surveillance under physiological conditions. However, excessive or chronic microglial activation results in the release of pro-inflammatory cytokines, reactive oxygen species (ROS), nitric oxide (NO), and excitotoxic mediators that contribute to neuronal injury (Block et al., 2007). Activated astrocytes further amplify inflammatory responses by secreting cytokines, chemokines, and inflammatory enzymes such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). Sustained glial activation ultimately disrupts neuronal homeostasis and synaptic integrity.

Among the most important inflammatory mediators involved in neuroinflammation are tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These cytokines regulate immune cell recruitment, neuronal signaling, apoptotic pathways, and oxidative stress responses. Elevated levels of TNF-α and IL-1β promote glutamate excitotoxicity by impairing astrocytic glutamate uptake and enhancing NMDA receptor-mediated calcium influx, thereby contributing to neuronal degeneration (Becher et al., 2017). IL-6 plays a dual role in neuroinflammation, acting as both a pro-inflammatory and neuroprotective cytokine depending on the disease stage and cellular context. Chronic elevation of inflammatory cytokines has been consistently reported in both schizophrenia and Parkinson’s disease, indicating sustained immune dysregulation in these disorders.

The nuclear factor kappa B (NF-κB) signaling pathway represents one of the primary molecular regulators of neuroinflammation. Activation of NF-κB in microglia and astrocytes induces transcription of numerous inflammatory genes including TNF-α, IL-6, IL-1β, COX-2, and iNOS (Lawrence, 2009). Oxidative stress, mitochondrial dysfunction, α-synuclein aggregates, and environmental toxins can activate NF-κB signaling, creating a self-perpetuating inflammatory cycle. Additionally, inflammasome activation, particularly the NLRP3 inflammasome, has been implicated in both SCZ and PD. Inflammasomes are intracellular multiprotein complexes that regulate maturation of IL-1β and IL-18 through caspase-1 activation. Excessive NLRP3 activation contributes to chronic neuroinflammation, neuronal apoptosis, and mitochondrial dysfunction (Heneka et al., 2018).

In schizophrenia, increasing evidence supports the hypothesis that immune dysregulation and neuroinflammation play central roles in disease pathogenesis. Elevated serum and cerebrospinal fluid levels of IL-6, TNF-α, IL-1β, and C-reactive protein (CRP) have been observed in patients with acute psychosis and chronic schizophrenia (Miller et al., 2011). Neuroimaging studies have demonstrated increased microglial activation in cortical and subcortical brain regions associated with cognitive and behavioral abnormalities. Prenatal infection and maternal immune activation are also strongly associated with increased risk of schizophrenia in offspring, suggesting that early-life immune disturbances may contribute to abnormal neurodevelopment (Brown & Derkits, 2010). Maternal exposure to viral infections, bacterial endotoxins, or inflammatory cytokines can alter fetal brain development through disruption of synaptic maturation, neurotransmitter signaling, and neuronal migration.

One of the most important neuroinflammatory mechanisms implicated in schizophrenia involves abnormal microglial-mediated synaptic pruning. During normal brain development, microglia eliminate excess synapses to refine neuronal circuits. However, excessive microglial activation may lead to pathological synaptic loss, particularly within cortical regions involved in cognition and executive functioning (Sellgren et al., 2019). Complement system dysregulation, especially increased complement component C4 expression, has been associated with enhanced synaptic pruning and schizophrenia susceptibility. This abnormal synaptic elimination may contribute to cognitive impairment, cortical thinning, and disrupted neural connectivity observed in schizophrenia patients.

Neuroinflammation is equally important in Parkinson’s disease, where chronic activation of glial cells contributes significantly to dopaminergic neuronal degeneration. Activated microglia are abundantly present within the substantia nigra of PD patients and release neurotoxic mediators including TNF-α, IL-1β, ROS, and prostaglandins (Hirsch & Hunot, 2009). Misfolded α-synuclein aggregates act as potent inflammatory stimuli that activate toll-like receptors (TLRs) on microglia, triggering NF-κB signaling and inflammasome activation. This inflammatory cascade exacerbates mitochondrial dysfunction and oxidative stress, thereby accelerating neuronal death. Astrocytes also contribute to disease progression through impaired glutamate regulation, inflammatory signaling, and reduced neurotrophic support.

In addition to resident glial activation, peripheral immune cell infiltration has been increasingly recognized in Parkinson’s disease. Disruption of the blood–brain barrier (BBB) permits infiltration of T lymphocytes, monocytes, and macrophages into the CNS, amplifying local inflammatory responses (Brochard et al., 2009). CD4+ and CD8+ T cells have been identified within the substantia nigra of PD patients, suggesting involvement of adaptive immune responses in dopaminergic neurodegeneration. Peripheral inflammatory conditions and systemic infections may further exacerbate CNS inflammation through cytokine-mediated signaling pathways.

Several shared immune-mediated mechanisms contribute to pathology in both schizophrenia and Parkinson’s disease. Blood–brain barrier dysfunction is increasingly recognized as a common pathological feature that permits entry of peripheral inflammatory mediators, immune cells, and neurotoxic molecules into the CNS. Increased BBB permeability disrupts neuronal homeostasis and enhances neuroimmune activation. Furthermore, cytokine-mediated neuronal injury contributes to synaptic dysfunction, mitochondrial impairment, and apoptosis in both disorders. Chronic inflammatory signaling also interacts closely with oxidative stress and mitochondrial dysfunction, forming a vicious cycle that amplifies neuronal damage. ROS generated during inflammation activate NF-κB and inflammasome pathways, while mitochondrial dysfunction promotes release of mitochondrial DNA and DAMPs that further stimulate immune responses (DiSabato et al., 2016).

Given the significant contribution of neuroinflammation to disease progression, anti-inflammatory therapeutic strategies are increasingly being explored for both SCZ and PD. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and celecoxib have shown potential adjunctive benefits in reducing inflammatory markers and improving psychiatric symptoms in schizophrenia (Müller et al., 2010). Similarly, anti-inflammatory agents targeting COX-2 and prostaglandin pathways have demonstrated neuroprotective effects in experimental PD models. Cytokine inhibitors targeting TNF-α, IL-1β, and IL-6 are also under investigation as potential disease-modifying therapies.

Natural anti-inflammatory phytochemicals have attracted considerable interest due to their antioxidant, neuroprotective, and immunomodulatory properties. Compounds such as curcumin, resveratrol, quercetin, epigallocatechin gallate (EGCG), and cannabidiol have demonstrated the ability to suppress NF-κB activation, inhibit pro-inflammatory cytokine release, and reduce oxidative stress in preclinical studies (Spagnuolo et al., 2018). These phytochemicals may provide safer multi-target therapeutic options capable of simultaneously modulating inflammation, mitochondrial dysfunction, and protein aggregation.

Microglial modulators represent another promising therapeutic strategy. Agents such as minocycline, pioglitazone, and colony-stimulating factor modulators can suppress excessive microglial activation and attenuate neuroinflammatory damage. Additionally, emerging nanotechnology-based drug delivery systems may improve blood–brain barrier penetration and enhance targeted delivery of anti-inflammatory therapeutics to affected brain regions. Collectively, these findings emphasize that neuroinflammation is not merely a secondary phenomenon but rather a central pathogenic driver linking schizophrenia and Parkinson’s disease, thereby offering important opportunities for translational multi-target drug development.

Table 1: Neuroinflammatory Biomarkers in Neurodegenerative Disorders

3. Mitochondrial Dysfunction and Bioenergetic Failure

Mitochondria are highly dynamic intracellular organelles that play a central role in neuronal survival, synaptic transmission, calcium buffering, redox regulation, and energy metabolism. Due to the exceptionally high metabolic demands of neurons, proper mitochondrial function is essential for maintaining neuronal integrity and neurotransmission. Increasing evidence indicates that mitochondrial dysfunction is a major pathological hallmark in both schizophrenia (SCZ) and Parkinson’s disease (PD), contributing to oxidative stress, synaptic abnormalities, neuroinflammation, and progressive neurodegeneration (Lin & Beal, 2006). Dysfunctional mitochondria impair neuronal bioenergetics and trigger apoptotic signaling pathways, thereby exacerbating disease progression. Emerging findings suggest that mitochondrial abnormalities may serve as a mechanistic link connecting psychiatric and neurodegenerative disorders.

One of the primary functions of mitochondria is ATP generation through oxidative phosphorylation within the electron transport chain (ETC). Neurons are highly dependent on aerobic metabolism due to their limited glycolytic capacity and constant requirement for ATP to sustain membrane potential, neurotransmitter release, axonal transport, and synaptic plasticity. The mitochondrial electron transport chain, particularly complexes I–V, facilitates oxidative phosphorylation and ATP synthesis. Any disruption in mitochondrial respiration results in cellular energy deficits, impaired neuronal signaling, and increased susceptibility to degeneration (Nunnari & Suomalainen, 2012). In both schizophrenia and Parkinson’s disease, impaired ATP production contributes to altered neuronal communication, synaptic dysfunction, and cognitive impairment.

Mitochondria also regulate intracellular calcium homeostasis, which is essential for neuronal excitability, neurotransmitter release, and synaptic plasticity. Mitochondria buffer cytosolic calcium through calcium uptake mechanisms and maintain cellular calcium balance during neuronal firing. Excessive calcium accumulation within mitochondria, however, can induce mitochondrial permeability transition pore (mPTP) opening, membrane depolarization, and activation of apoptotic cascades (Mattson et al., 2008). Dysregulated calcium signaling has been implicated in excitotoxic neuronal damage in both SCZ and PD. In schizophrenia, glutamatergic dysfunction and NMDA receptor abnormalities may contribute to altered calcium homeostasis, whereas in Parkinson’s disease, excessive calcium influx in dopaminergic neurons increases mitochondrial stress and vulnerability.

Another crucial role of mitochondria involves regulation of reactive oxygen species (ROS). Under physiological conditions, mitochondria generate low levels of ROS as byproducts of oxidative phosphorylation, which participate in intracellular signaling and redox homeostasis. However, dysfunctional mitochondria produce excessive ROS that damage proteins, lipids, mitochondrial DNA (mtDNA), and neuronal membranes (Murphy, 2009). Elevated oxidative stress further impairs mitochondrial function, creating a vicious cycle of neuronal injury and energy failure. Since neurons possess limited antioxidant defense capacity, excessive mitochondrial ROS production is particularly detrimental to CNS function.

Mitochondrial abnormalities have been extensively reported in schizophrenia, suggesting that impaired cellular energetics may contribute significantly to disease pathophysiology. Neuroimaging and postmortem studies have demonstrated reduced cerebral glucose metabolism, altered ATP synthesis, and impaired oxidative phosphorylation in schizophrenia patients (Prabakaran et al., 2004). Several studies have identified decreased activity of mitochondrial respiratory chain enzymes, particularly complex I and complex IV, within cortical and hippocampal regions associated with cognition and executive functioning. Deficits in energy metabolism may contribute to impaired synaptic plasticity, disrupted neural connectivity, and cognitive dysfunction commonly observed in schizophrenia.

Genetic studies further support the involvement of mitochondrial dysfunction in schizophrenia. Altered expression of mitochondrial genes related to oxidative phosphorylation, calcium signaling, and ATP production has been identified in schizophrenia patients (Clay et al., 2011). Mutations and polymorphisms affecting mitochondrial proteins such as DISC1 (Disrupted-in-Schizophrenia 1) have also been associated with impaired mitochondrial trafficking and altered neuronal bioenergetics. DISC1 regulates mitochondrial transport along axons and dendrites, which is essential for maintaining synaptic energy supply. Dysfunctional mitochondrial dynamics may therefore contribute to abnormal neuronal connectivity and cortical dysfunction in schizophrenia.

Reduced cerebral energy metabolism is another prominent feature of schizophrenia. Magnetic resonance spectroscopy (MRS) studies have demonstrated abnormalities in brain lactate, phosphocreatine, and ATP levels, indicating impaired mitochondrial respiration and altered bioenergetics (Rowland et al., 2016). These metabolic disturbances may contribute to cognitive deficits, negative symptoms, and impaired neuronal communication. Furthermore, mitochondrial dysfunction interacts closely with oxidative stress and neuroinflammation, thereby amplifying neuronal damage and synaptic abnormalities in schizophrenia.

Mitochondrial injury is even more prominently implicated in Parkinson’s disease, where degeneration of dopaminergic neurons is strongly associated with impaired mitochondrial respiration and oxidative stress. One of the most extensively studied mechanisms in PD involves inhibition of mitochondrial complex I within the electron transport chain. Environmental neurotoxins such as MPTP and rotenone induce Parkinsonian symptoms by selectively inhibiting complex I activity, leading to ATP depletion and excessive ROS production (Schapira et al., 1990). Reduced complex I activity has also been identified in the substantia nigra and peripheral tissues of PD patients, indicating systemic mitochondrial impairment.

Defective mitophagy represents another key mitochondrial abnormality in Parkinson’s disease. Mitophagy is the selective autophagic removal of damaged mitochondria and is essential for maintaining mitochondrial quality control. The PINK1/Parkin pathway plays a critical role in identifying and eliminating dysfunctional mitochondria. Under normal conditions, PINK1 accumulates on damaged mitochondrial membranes and recruits the E3 ubiquitin ligase Parkin, which initiates mitophagic degradation (Pickrell & Youle, 2015). Mutations in PINK1 and Parkin genes impair mitochondrial clearance, leading to accumulation of defective mitochondria, oxidative stress, and neuronal degeneration. Dysfunctional mitophagy is therefore considered a central pathogenic mechanism in familial and sporadic PD.

Dopaminergic neurons within the substantia nigra are particularly vulnerable to mitochondrial injury due to their high metabolic demands, autonomous pacemaking activity, and dopamine metabolism. Dopamine oxidation generates ROS and toxic quinones that further damage mitochondrial proteins and membranes (Dias et al., 2013). Additionally, these neurons possess extensive axonal arborization and require substantial ATP to maintain synaptic transmission. Consequently, even minor impairments in mitochondrial function can significantly affect neuronal survival. Iron accumulation within the substantia nigra further exacerbates oxidative damage through Fenton chemistry-mediated ROS generation.

An important aspect of mitochondrial pathology in both schizophrenia and Parkinson’s disease involves the bidirectional interaction between mitochondrial dysfunction and neuroinflammation. Excessive ROS production from damaged mitochondria activates inflammatory signaling pathways including NF-κB and NLRP3 inflammasome activation (West et al., 2011). ROS-induced inflammatory signaling stimulates microglial activation and cytokine release, which in turn further impair mitochondrial respiration and ATP production. This vicious cycle amplifies neuronal injury and accelerates neurodegeneration.

Mitochondrial DNA release also contributes significantly to neuroinflammatory activation. Damaged mitochondria release mtDNA into the cytoplasm and extracellular environment, where it acts as a damage-associated molecular pattern (DAMP) capable of activating innate immune receptors such as toll-like receptor 9 (TLR9) and inflammasome pathways (Riley & Tait, 2020). This process enhances production of pro-inflammatory cytokines including IL-1β and TNF-α, thereby perpetuating chronic neuroinflammation. The interaction among mitochondrial dysfunction, oxidative stress, and immune activation forms a self-propagating neurodegenerative cascade that contributes to progressive neuronal loss in SCZ and PD.

Given the central role of mitochondrial dysfunction in neurodegeneration and psychiatric disorders, several mitochondria-targeted therapeutic strategies are currently under investigation. Coenzyme Q10 (CoQ10), an essential component of the electron transport chain and endogenous antioxidant, has shown neuroprotective effects through enhancement of mitochondrial respiration and reduction of oxidative stress (Beal, 2003). Although clinical results have been mixed, CoQ10 remains a promising adjunctive therapy for mitochondrial support.

Mitochondrial antioxidants specifically designed to target mitochondrial ROS have also gained considerable attention. Compounds such as MitoQ, SkQ1, and SS peptides selectively accumulate within mitochondria and neutralize oxidative damage more effectively than conventional antioxidants (Smith & Murphy, 2010). These agents may help preserve mitochondrial membrane integrity, improve ATP production, and reduce inflammatory signaling.

Nicotinamide adenine dinucleotide (NAD+) boosters represent another emerging therapeutic approach. NAD+ is essential for mitochondrial metabolism, DNA repair, and cellular energy production. Declining NAD+ levels have been associated with aging, mitochondrial dysfunction, and neurodegeneration. Agents such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) enhance NAD+ biosynthesis and improve mitochondrial function, neuronal survival, and cellular resilience (Verdin, 2015).

Peptide-based mitochondrial protectants are also being explored for their neuroprotective potential. Mitochondria-targeting peptides such as SS-31 (elamipretide) stabilize mitochondrial membranes, reduce ROS generation, and improve electron transport chain efficiency. These peptides may protect neurons from apoptosis and bioenergetic failure while simultaneously attenuating neuroinflammation and oxidative stress.

Overall, mitochondrial dysfunction represents a central pathogenic mechanism linking schizophrenia and Parkinson’s disease through impaired bioenergetics, oxidative stress, neuroinflammation, and synaptic degeneration. Targeting mitochondrial pathways may therefore provide promising translational opportunities for the development of multi-target therapeutics capable of slowing disease progression and improving neurological function in both disorders.

Table 2: Mitochondrial Dysfunction-Associated Genes and Proteins

4. Oxidative Stress and Redox Imbalance

Oxidative stress is widely recognized as a major pathogenic mechanism contributing to neuronal dysfunction, synaptic degeneration, and progressive neurodegeneration in both schizophrenia (SCZ) and Parkinson’s disease (PD). The brain is particularly susceptible to oxidative injury because of its high oxygen consumption, abundant lipid content, elevated metabolic activity, and relatively limited antioxidant defense capacity. Oxidative stress occurs when the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) exceeds the capacity of endogenous antioxidant systems to neutralize them, resulting in cellular damage and disruption of redox homeostasis (Betteridge, 2000). Increasing evidence suggests that oxidative stress acts as a central molecular bridge linking mitochondrial dysfunction, neuroinflammation, protein misfolding, and synaptic abnormalities in neuropsychiatric and neurodegenerative disorders.

Reactive oxygen species and reactive nitrogen species are generated through multiple cellular processes under physiological and pathological conditions. Major ROS include superoxide anion (O?•−), hydroxyl radical (•OH), hydrogen peroxide (H?O?), and singlet oxygen, whereas RNS primarily include nitric oxide (NO) and peroxynitrite (ONOO−). Mitochondria represent the primary intracellular source of ROS due to electron leakage from the electron transport chain during oxidative phosphorylation (Murphy, 2009). Leakage of electrons from mitochondrial complexes I and III results in partial reduction of oxygen and formation of superoxide radicals. Under normal conditions, antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase convert ROS into less toxic molecules. However, mitochondrial dysfunction, inflammation, environmental toxins, and impaired antioxidant defenses can dramatically increase ROS production.

Additional cellular sources of ROS/RNS include activated microglia, NADPH oxidase enzymes, xanthine oxidase, peroxisomes, and dopamine metabolism. Activated microglia generate large quantities of ROS and nitric oxide during neuroinflammatory responses through induction of inducible nitric oxide synthase (iNOS) and NADPH oxidase pathways (Block & Hong, 2005). Excessive nitric oxide reacts with superoxide radicals to produce peroxynitrite, a highly reactive molecule capable of damaging proteins, lipids, mitochondrial enzymes, and DNA. Environmental toxins, heavy metals, and radiation exposure may also contribute to ROS generation and oxidative neuronal injury.

Oxidative injury mechanisms involve widespread damage to cellular macromolecules including lipids, proteins, carbohydrates, and nucleic acids. Lipid peroxidation is particularly detrimental within the CNS because neuronal membranes are rich in polyunsaturated fatty acids that are highly susceptible to ROS attack. Peroxidation of membrane lipids disrupts membrane fluidity, ion channel function, receptor signaling, and synaptic transmission (Halliwell, 2006). Oxidative modification of proteins results in enzyme inactivation, protein aggregation, and impaired cellular signaling, while oxidative DNA damage contributes to genomic instability, mitochondrial dysfunction, and apoptosis. Collectively, these oxidative processes impair neuronal viability and accelerate neurodegenerative cascades.

Oxidative stress has been extensively implicated in the pathophysiology of schizophrenia. One of the most consistently reported findings in schizophrenia patients is reduced glutathione (GSH) levels within the brain and peripheral tissues (Do et al., 2009). Glutathione is the principal intracellular antioxidant responsible for detoxifying ROS and maintaining redox balance. Deficient glutathione levels impair the cellular capacity to neutralize oxidative radicals, rendering neurons more vulnerable to oxidative injury. Reduced GSH concentrations have been observed particularly within the prefrontal cortex and cerebrospinal fluid of schizophrenia patients and are strongly associated with cognitive dysfunction and negative symptoms.

Lipid peroxidation is another important feature of oxidative stress in schizophrenia. Elevated levels of malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARS), and 4-hydroxynonenal (4-HNE) have been reported in schizophrenia patients, indicating increased oxidative damage to neuronal membranes (Flatow et al., 2013). Oxidative lipid damage may disrupt synaptic membrane integrity, neurotransmitter receptor function, and neuronal connectivity, thereby contributing to psychotic symptoms and cognitive deficits. Furthermore, increased oxidative stress may interfere with dopamine and glutamate neurotransmission, exacerbating neurochemical abnormalities associated with schizophrenia.

Imbalance of antioxidant enzymes has also been widely documented in schizophrenia. Reduced activity of superoxide dismutase (SOD), catalase, and glutathione peroxidase has been observed in both central and peripheral tissues of affected individuals (Yao & Keshavan, 2011). Impaired antioxidant enzyme function further compromises neuronal defense mechanisms against ROS-induced injury. Oxidative stress is additionally linked to mitochondrial dysfunction and neuroinflammation in schizophrenia, creating a self-amplifying cycle of neuronal damage and synaptic dysregulation.

In Parkinson’s disease, oxidative stress is considered one of the principal mechanisms driving degeneration of dopaminergic neurons within the substantia nigra. Dopamine metabolism itself is a significant source of oxidative stress because dopamine undergoes enzymatic and non-enzymatic oxidation to generate hydrogen peroxide, superoxide radicals, and dopamine quinones (Dias et al., 2013). These reactive intermediates damage mitochondrial proteins, lipids, and DNA while promoting α-synuclein aggregation and neuronal apoptosis. Dopaminergic neurons are therefore intrinsically susceptible to oxidative injury due to continuous dopamine turnover and high metabolic activity.

Iron accumulation within the substantia nigra further contributes to oxidative stress in Parkinson’s disease. Elevated iron concentrations have been consistently identified in PD brains and are believed to promote ROS generation through Fenton and Haber–Weiss reactions (Ward et al., 2014). Iron catalyzes conversion of hydrogen peroxide into highly reactive hydroxyl radicals capable of causing severe neuronal damage. Additionally, impaired iron homeostasis may accelerate α-synuclein aggregation and mitochondrial dysfunction, thereby amplifying neurodegenerative processes.

Oxidative neuronal degeneration in PD involves extensive damage to mitochondrial membranes, respiratory chain enzymes, cytoskeletal proteins, and nucleic acids. Increased levels of lipid peroxidation products, oxidized proteins, and DNA oxidation markers such as 8-hydroxydeoxyguanosine (8-OHdG) have been identified in the substantia nigra of Parkinson’s patients (Jenner, 2003). Oxidative stress also contributes to impairment of mitochondrial complex I activity and activation of apoptotic signaling pathways. Since dopaminergic neurons possess relatively low antioxidant defense capacity compared to other neuronal populations, they are particularly vulnerable to oxidative degeneration.

An important aspect of oxidative stress pathology in both schizophrenia and Parkinson’s disease involves its interaction with mitochondrial dysfunction and neuroinflammation. Excessive ROS production activates inflammatory signaling pathways including NF-κB, MAPK, and NLRP3 inflammasome activation, leading to increased expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 (Mittal et al., 2014). ROS-mediated cytokine activation further stimulates microglial activation and inflammatory responses, thereby perpetuating neuronal injury. Simultaneously, inflammatory cytokines impair mitochondrial respiration and ATP synthesis, leading to additional ROS production. This bidirectional relationship between oxidative stress and inflammation forms a vicious neurodegenerative cycle.

Oxidative damage to proteins and DNA further exacerbates disease progression in SCZ and PD. Oxidized proteins often lose functional integrity and become prone to aggregation, contributing to proteostasis dysfunction and impaired synaptic signaling. Oxidative DNA damage affects both nuclear and mitochondrial genomes, impairing transcriptional regulation and mitochondrial bioenergetics. Mitochondrial DNA is especially vulnerable to ROS due to its close proximity to the electron transport chain and limited DNA repair capacity. Accumulation of oxidative DNA damage contributes to neuronal senescence, apoptosis, and progressive neurodegeneration.

Given the central role of oxidative stress in disease pathogenesis, antioxidant-based therapeutic strategies are increasingly being investigated for schizophrenia and Parkinson’s disease. N-acetylcysteine (NAC), a precursor of glutathione, has demonstrated promising neuroprotective effects through restoration of intracellular GSH levels and reduction of oxidative stress (Berk et al., 2013). NAC has shown potential benefits in improving negative symptoms and cognitive impairment in schizophrenia while also exhibiting neuroprotective effects in PD models.

Natural polyphenols and flavonoids have attracted considerable attention because of their potent antioxidant, anti-inflammatory, and neuroprotective properties. Compounds such as curcumin, quercetin, resveratrol, epigallocatechin gallate (EGCG), and luteolin can scavenge free radicals, inhibit lipid peroxidation, modulate inflammatory pathways, and improve mitochondrial function (Spagnuolo et al., 2018). Many of these phytochemicals additionally inhibit α-synuclein aggregation and support neuronal survival, making them promising multi-target therapeutic agents.

Selenium and melatonin have also shown significant antioxidant potential in neurodegenerative and psychiatric disorders. Selenium serves as an essential cofactor for glutathione peroxidase and other antioxidant enzymes, while melatonin directly scavenges ROS and enhances mitochondrial function (Reiter et al., 2014). Melatonin additionally exhibits anti-inflammatory and anti-apoptotic effects, making it particularly attractive for neuroprotection.

Advances in nanotechnology have facilitated the development of nano-antioxidant formulations designed to improve bioavailability, blood–brain barrier penetration, and targeted delivery of antioxidant compounds. Nanoparticles loaded with curcumin, resveratrol, cerium oxide, selenium, or antioxidant enzymes have demonstrated enhanced neuroprotective efficacy in experimental models (Kwon et al., 2018). These nanoformulations may overcome limitations associated with poor solubility, rapid metabolism, and limited CNS delivery of conventional antioxidants.

Overall, oxidative stress and redox imbalance represent central pathological mechanisms linking schizophrenia and Parkinson’s disease through interactions with mitochondrial dysfunction, neuroinflammation, protein aggregation, and synaptic injury. Targeting oxidative pathways through antioxidant therapies, mitochondrial stabilizers, and nanotechnology-based interventions may therefore provide promising translational strategies for multi-target neuroprotective drug development.

Table 3: Oxidative Stress Markers and Antioxidant Therapies

5. Protein Misfolding and Proteostasis Dysfunction

Protein homeostasis (proteostasis) is essential for maintaining neuronal integrity, synaptic function, and cellular survival. It involves a tightly regulated network responsible for proper protein synthesis, folding, trafficking, and degradation. Neurons are particularly vulnerable to proteostatic imbalance due to their long lifespan, high metabolic demand, and limited regenerative capacity. Disruption of proteostasis leads to accumulation of misfolded or aggregated proteins, which can impair synaptic signaling, trigger endoplasmic reticulum (ER) stress, activate inflammatory pathways, and ultimately induce neurodegeneration. Increasing evidence suggests that protein misfolding and proteostasis failure represent shared pathological mechanisms in both Parkinson’s disease (PD) and schizophrenia (SCZ), linking neurodegenerative and psychiatric disease spectra (Hipp et al., 2019).

Molecular chaperones play a central role in proteostasis by assisting nascent polypeptides in achieving correct three-dimensional conformations and preventing aggregation of misfolded proteins. Heat shock proteins (HSPs), including HSP70 and HSP90, are key chaperone families that stabilize unfolded proteins and facilitate refolding or degradation. When protein misfolding exceeds the capacity of chaperone systems, cells activate compensatory degradation pathways such as the ubiquitin–proteasome system (UPS) and autophagy-lysosomal pathway. The UPS selectively degrades short-lived or damaged proteins via ubiquitination, whereas autophagy is responsible for the degradation of long-lived proteins, protein aggregates, and dysfunctional organelles through lysosomal processing (Ciechanover & Kwon, 2017). Dysfunction in these quality control systems results in toxic protein accumulation and neuronal injury.

Protein misfolding is a hallmark feature of Parkinson’s disease, most notably characterized by aggregation of α-synuclein into insoluble fibrils. α-Synuclein is a presynaptic neuronal protein involved in synaptic vesicle regulation; however, under pathological conditions it undergoes misfolding and aggregation, forming oligomers and fibrils that accumulate as Lewy bodies in dopaminergic neurons of the substantia nigra. These aggregates disrupt synaptic transmission, impair mitochondrial function, and activate inflammatory responses (Spillantini et al., 1997). Soluble oligomeric forms of α-synuclein are considered particularly neurotoxic due to their ability to disrupt membrane integrity and calcium homeostasis.

A critical and emerging concept in Parkinson’s disease pathology is the prion-like propagation of misfolded α-synuclein. Misfolded α-synuclein can spread from neuron to neuron in a templated manner, inducing misfolding of native α-synuclein in recipient cells. This process facilitates progressive disease spread across interconnected brain regions, consistent with the staged progression observed clinically (Braak et al., 2003). Such propagation mechanisms position PD within a broader category of protein misfolding disorders with self-amplifying pathological spread.

In schizophrenia, protein misfolding is less overt but increasingly recognized as a contributing factor in synaptic dysfunction and neurodevelopmental abnormalities. One of the most studied proteins in this context is Disrupted-in-Schizophrenia 1 (DISC1), a scaffolding protein involved in neuronal development, synaptic formation, and intracellular signaling. Abnormal DISC1 folding or aggregation can disrupt mitochondrial transport, synaptic plasticity, and neuronal connectivity, contributing to cognitive and behavioral deficits observed in schizophrenia (Brandon & Sawa, 2011). Although not forming classical amyloid aggregates like α-synuclein, DISC1 dysfunction reflects a broader proteostatic imbalance affecting neuronal function.

Another important protein implicated in schizophrenia is dysbindin (DTNBP1), which plays a role in synaptic vesicle trafficking, neurotransmitter release, and receptor regulation. Altered expression or dysfunction of dysbindin has been associated with impaired glutamatergic and dopaminergic signaling, both of which are central to schizophrenia pathophysiology. Dysregulation of synaptic proteins more broadly contributes to impaired synaptic plasticity and cortical connectivity abnormalities. Additionally, abnormalities in other synaptic proteins, including neuregulin-1 (NRG1) and postsynaptic density proteins, further highlight the importance of proteostasis in maintaining synaptic integrity.

Endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) are increasingly recognized in schizophrenia. ER stress occurs when misfolded proteins accumulate within the ER lumen, triggering adaptive signaling pathways aimed at restoring proteostasis. The UPR involves activation of key sensors such as PERK, IRE1, and ATF6, which collectively reduce protein translation, enhance chaperone expression, and promote degradation of misfolded proteins. However, chronic ER stress leads to apoptotic signaling and neuronal dysfunction (Calabrò et al., 2021). Evidence of ER stress markers has been reported in postmortem brain tissues of schizophrenia patients, suggesting sustained proteostatic imbalance.

Several shared proteotoxic mechanisms contribute to neuronal dysfunction in both Parkinson’s disease and schizophrenia. One of the most important is impaired autophagy, which leads to accumulation of damaged proteins and organelles. Dysfunction of autophagy-related genes and lysosomal pathways has been implicated in both disorders, resulting in reduced clearance of aggregated proteins and increased cellular stress. In Parkinson’s disease, mutations in genes such as LRRK2, GBA, and SNCA are directly linked to impaired lysosomal function and autophagic clearance (Menzies et al., 2017). In schizophrenia, dysregulation of autophagy-related signaling pathways has also been observed, contributing to synaptic protein abnormalities and neuronal dysfunction.

Oxidative stress further exacerbates protein misfolding by inducing oxidative modifications of amino acid residues, leading to structural instability and aggregation propensity. Oxidatively modified proteins are more prone to misfolding and resistance to proteasomal degradation. This creates a synergistic interaction between oxidative stress and proteostasis failure, amplifying neuronal injury. In addition, mitochondrial dysfunction interacts closely with protein quality control systems. Mitochondria are both sources and targets of misfolded proteins, and impaired mitochondrial function can disrupt ATP-dependent proteasomal and autophagic processes, further worsening proteostatic imbalance.

Mitochondrial–protein interactions are particularly important in neurodegenerative disease progression. Aggregated proteins such as α-synuclein can directly associate with mitochondrial membranes, impairing electron transport chain function, increasing ROS production, and triggering apoptotic pathways. Conversely, mitochondrial dysfunction enhances protein misfolding by increasing oxidative stress and reducing ATP availability required for protein folding and degradation systems. This bidirectional relationship forms a self-reinforcing cycle of proteotoxicity and energy failure.

Given the central role of proteostasis dysfunction in neurodegenerative and psychiatric disorders, several therapeutic strategies targeting protein misfolding are under active investigation. Molecular chaperone enhancers aim to boost the cellular protein-folding capacity by upregulating heat shock proteins, thereby reducing aggregation and improving protein quality control. Pharmacological agents such as HSP90 inhibitors and heat shock factor-1 (HSF1) activators are being explored for their ability to restore proteostasis and protect neuronal function.

Autophagy activators represent another promising therapeutic approach. Agents such as rapamycin, trehalose, and mTOR inhibitors enhance autophagic flux and promote clearance of aggregated proteins and damaged organelles. By restoring lysosomal degradation pathways, autophagy activation may help reduce toxic protein accumulation in both schizophrenia and Parkinson’s disease. Modulation of lysosomal function is particularly relevant in PD, where lysosomal dysfunction plays a central role in α-synuclein accumulation.

Small-molecule aggregation inhibitors are also being developed to directly prevent misfolding or aggregation of disease-associated proteins. These compounds may stabilize native protein conformations, inhibit oligomer formation, or disrupt fibril assembly. In Parkinson’s disease, inhibitors targeting α-synuclein aggregation are currently in preclinical and clinical development. Similar approaches may be adapted for synaptic protein stabilization in schizophrenia.

Immunotherapy approaches, including passive and active vaccination strategies, represent an emerging frontier in the treatment of protein misfolding disorders. Monoclonal antibodies targeting α-synuclein have shown promise in reducing extracellular propagation of toxic aggregates and slowing disease progression in Parkinson’s disease models. Although still experimental, similar immunotherapeutic strategies may be applicable to other misfolded proteins involved in psychiatric disorders.

Overall, protein misfolding and proteostasis dysfunction represent a convergent pathological mechanism linking schizophrenia and Parkinson’s disease. Disruption of protein quality control systems, combined with oxidative stress, mitochondrial dysfunction, and impaired autophagy, creates a toxic intracellular environment that drives synaptic failure and neurodegeneration. Therapeutic strategies aimed at restoring proteostasis offer significant potential for the development of disease-modifying, multi-target interventions across both neuropsychiatric and neurodegenerative disease spectra.

6. Synaptic Dysfunction and Neurotransmission Abnormalities

Synaptic dysfunction is increasingly recognized as a core pathological feature shared by both schizophrenia (SCZ) and Parkinson’s disease (PD), linking molecular disturbances to clinical manifestations such as cognitive impairment, motor dysfunction, and behavioral abnormalities. Synapses represent highly specialized structures responsible for neurotransmission, neural network integration, and activity-dependent plasticity. Proper synaptic function depends on coordinated processes including synapse formation, maturation, pruning, and elimination. Disruption of these processes leads to impaired neural connectivity and circuit-level dysfunction, which is now considered a central mechanism in neuropsychiatric and neurodegenerative disorders (Penzes et al., 2011).

Synaptic plasticity refers to the ability of synapses to strengthen or weaken over time in response to activity, forming the biological basis of learning and memory. Two fundamental mechanisms of synaptic plasticity are long-term potentiation (LTP) and long-term depression (LTD). LTP enhances synaptic strength through increased receptor density and neurotransmitter release, while LTD weakens synaptic transmission via receptor internalization and synaptic remodeling. Balanced LTP and LTD are essential for maintaining optimal neural circuitry. Dysregulation of these processes leads to impaired cognitive function, memory deficits, and abnormal behavioral responses observed in both SCZ and PD.

Synapse formation and pruning are tightly regulated during neurodevelopment and continue throughout life to maintain neural circuit efficiency. Microglia play a crucial role in synaptic pruning by eliminating weak or unnecessary synapses via complement-mediated mechanisms. However, excessive or insufficient pruning can result in abnormal synaptic connectivity. In schizophrenia, excessive synaptic pruning during adolescence is strongly implicated in cortical thinning and cognitive dysfunction, whereas in Parkinson’s disease, progressive synaptic loss contributes to both motor and non-motor symptoms, particularly cognitive decline in later stages (Stevens et al., 2007).

Synaptic dysfunction in schizophrenia is strongly associated with dysregulation of multiple neurotransmitter systems, particularly dopamine, glutamate, and gamma-aminobutyric acid (GABA). The dopamine hypothesis of schizophrenia proposes hyperactivity of dopaminergic transmission in mesolimbic pathways, leading to positive symptoms such as hallucinations and delusions, while reduced dopamine activity in mesocortical pathways contributes to negative and cognitive symptoms (Howes & Kapur, 2009). This imbalance disrupts reward processing, motivation, and executive function.

In addition to dopaminergic abnormalities, NMDA receptor hypofunction on glutamatergic neurons is a key mechanism underlying schizophrenia pathology. Reduced NMDA receptor activity impairs excitatory neurotransmission, synaptic plasticity, and cortical network synchronization. NMDA receptor antagonists such as ketamine and phencyclidine (PCP) induce schizophrenia-like symptoms, supporting the glutamate hypothesis of schizophrenia (Coyle, 2006). This hypofunction also disrupts GABAergic interneuron activity, particularly parvalbumin-positive interneurons, leading to impaired cortical oscillations and cognitive dysfunction.

GABAergic abnormalities further contribute to synaptic dysfunction in schizophrenia. Reduced expression of GABA-synthesizing enzymes such as glutamic acid decarboxylase (GAD67) has been observed in postmortem brain studies. This leads to impaired inhibitory neurotransmission and disruption of excitatory–inhibitory balance within cortical circuits. The resulting neural network instability contributes to cognitive deficits, working memory impairment, and sensory processing abnormalities characteristic of schizophrenia.

In Parkinson’s disease, synaptic dysfunction is primarily driven by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to depletion of dopamine in the striatum. This dopamine deficiency disrupts the basal ganglia circuitry, which regulates voluntary motor control, procedural learning, and reward processing. The imbalance between the direct and indirect pathways of the basal ganglia results in motor symptoms such as bradykinesia, rigidity, and tremor (Obeso et al., 2008).

Beyond motor dysfunction, synaptic abnormalities also contribute significantly to cognitive decline and neuropsychiatric symptoms in Parkinson’s disease. Synaptic loss in cortical and hippocampal regions is associated with dementia, depression, and executive dysfunction. α-Synuclein aggregation at presynaptic terminals disrupts synaptic vesicle trafficking, neurotransmitter release, and synaptic vesicle recycling. This leads to progressive synaptic failure even before overt neuronal death, highlighting synaptic dysfunction as an early event in PD pathogenesis (Kramer & Schulz-Schaeffer, 2007).

Shared synaptic pathomechanisms between schizophrenia and Parkinson’s disease involve disruptions in neurotransmitter balance, synaptic mitochondrial dysfunction, and neuroinflammation-induced synaptic degeneration. Neurotransmitter imbalance, particularly involving dopamine and glutamate systems, is central to both disorders. While schizophrenia is characterized by dysregulated dopaminergic signaling and glutamatergic hypofunction, Parkinson’s disease involves dopamine depletion accompanied by secondary glutamatergic hyperactivity in basal ganglia circuits. These opposing yet interconnected alterations highlight the complex role of neurotransmitter systems in synaptic homeostasis.

Synaptic mitochondrial dysfunction plays a crucial role in impairing synaptic transmission and plasticity. Synapses are highly energy-dependent structures requiring continuous ATP supply for vesicle cycling, ion transport, and receptor trafficking. Mitochondria localized at presynaptic and postsynaptic terminals regulate calcium buffering and ATP production. Mitochondrial dysfunction leads to impaired synaptic vesicle release, reduced neurotransmitter availability, and synaptic failure. In both SCZ and PD, mitochondrial deficits at synaptic terminals contribute to impaired neural connectivity and cognitive dysfunction.

Neuroinflammation also plays a significant role in synaptic degeneration. Activated microglia release pro-inflammatory cytokines such as TNF-α and IL-1β, which directly affect synaptic structure and function. TNF-α has been shown to regulate synaptic scaling by modulating AMPA receptor trafficking, and excessive TNF-α signaling leads to synaptic weakening and loss. Additionally, complement-mediated synaptic pruning driven by microglial activation contributes to excessive synapse elimination in schizophrenia and progressive synaptic loss in Parkinson’s disease (Hong et al., 2016). This inflammatory synaptic remodeling highlights the interplay between immune activation and neural connectivity.

Synapse-protective therapeutic approaches are increasingly being explored as potential disease-modifying strategies for both disorders. Glutamatergic modulators, including NMDA receptor co-agonists such as glycine and D-serine, as well as mGluR-targeting agents, aim to restore excitatory–inhibitory balance and improve cognitive function in schizophrenia. In Parkinson’s disease, modulation of glutamatergic signaling may also help reduce excitotoxicity and improve motor symptoms.

Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) play essential roles in synaptic survival, growth, and plasticity. Reduced levels of these neurotrophic factors have been observed in both SCZ and PD. Therapeutic delivery of neurotrophic factors or activation of their signaling pathways may enhance synaptic resilience and promote neuronal survival.

Synaptic repair strategies targeting cytoskeletal stability, vesicle trafficking, and receptor regulation are also under investigation. These approaches aim to restore synaptic architecture and improve neurotransmission efficiency. In addition, emerging stem cell-based therapies offer the potential for synaptic regeneration by replacing lost or dysfunctional neurons and restoring neural circuitry. Induced pluripotent stem cells (iPSCs) and neural progenitor cells have shown promise in preclinical models of Parkinson’s disease and are being explored for broader neuropsychiatric applications.

Overall, synaptic dysfunction represents a convergent pathological mechanism in schizophrenia and Parkinson’s disease, linking molecular abnormalities to circuit-level disturbances and clinical symptoms. Targeting synaptic pathways through neurotransmitter modulation, mitochondrial support, anti-inflammatory strategies, and regenerative therapies offers a promising direction for the development of multi-target interventions aimed at restoring neural connectivity and functional outcomes in both disorders.

7. Molecular Crosstalk Among Pathogenic Pathways

Neuroinflammation, oxidative stress, mitochondrial dysfunction, protein misfolding, and synaptic abnormalities do not operate as isolated events but rather function as an interconnected pathological network that drives progressive neuronal dysfunction in both schizophrenia (SCZ) and Parkinson’s disease (PD). Increasing evidence supports the concept that these mechanisms form an integrated disease system in which disturbances in one pathway amplify dysfunction in others, creating a self-perpetuating neurodegenerative cascade (Glass et al., 2010; Heneka et al., 2018). This systems-level interaction provides a mechanistic framework for understanding disease complexity and heterogeneity across neuropsychiatric and neurodegenerative disorders.

At the core of this integrated disease network is the dynamic interaction between inflammation, reactive oxygen species (ROS), mitochondrial dysfunction, and protein aggregation. Activated microglia release pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which stimulate ROS production through NADPH oxidase activation and mitochondrial impairment. In parallel, excessive ROS damages mitochondrial respiratory complexes, leading to reduced ATP production and further ROS generation. Mitochondrial dysfunction promotes release of mitochondrial DNA and other damage-associated molecular patterns (DAMPs), which further activate innate immune responses, thereby reinforcing neuroinflammation. Protein aggregation, particularly α-synuclein in PD and synaptic protein abnormalities in SCZ, exacerbates mitochondrial stress and inflammatory signaling, completing a tightly interconnected pathogenic loop.

From a systems biology perspective, these interactions can be better understood through multi-omics integration approaches that include genomics, transcriptomics, proteomics, metabolomics, and epigenomics. These high-throughput datasets enable identification of dysregulated molecular pathways and key regulatory hubs involved in disease progression. Gene–protein interaction networks constructed using bioinformatics tools reveal that pathways related to immune activation, mitochondrial metabolism, oxidative phosphorylation, and synaptic signaling are highly interconnected in both SCZ and PD (Gaiteri et al., 2014). Such network-based analyses provide insights into disease heterogeneity and identify potential convergent therapeutic targets.

Multi-omics approaches also facilitate biomarker discovery for early diagnosis, disease progression monitoring, and therapeutic response prediction. In schizophrenia, altered expression of inflammatory cytokines, oxidative stress markers, and synaptic proteins has been identified through transcriptomic and proteomic profiling. In Parkinson’s disease, metabolomic and proteomic studies have revealed alterations in mitochondrial metabolites, lipid peroxidation products, and α-synuclein levels. Integrating these datasets enables identification of shared biomarkers that reflect underlying neurodegenerative processes across both disorders.

A critical feature of molecular crosstalk in SCZ and PD is the presence of self-amplifying feedback loops that accelerate neurodegeneration. One of the most important is the ROS–inflammation cycle, where excessive ROS production activates NF-κB and inflammasome signaling pathways, leading to increased cytokine release, which in turn promotes further ROS generation. This cycle creates persistent oxidative and inflammatory stress that progressively damages neurons.

Another major feedback loop involves mitochondrial collapse and synaptic failure. Mitochondrial dysfunction reduces ATP availability at synaptic terminals, impairing neurotransmitter release, synaptic vesicle cycling, and calcium buffering. Synaptic failure further disrupts neuronal activity, leading to increased excitotoxicity and metabolic stress, which exacerbates mitochondrial damage. This bidirectional relationship results in progressive synaptic degeneration and circuit dysfunction.

Protein aggregation also contributes to neurodegeneration through toxic gain-of-function effects. Misfolded proteins such as α-synuclein disrupt mitochondrial function, impair proteostasis systems, and activate inflammatory pathways. Aggregated proteins can propagate between cells in a prion-like manner, amplifying disease spread and neuronal loss. Together, these feedback mechanisms establish a self-reinforcing network of pathological interactions that underlies disease progression in both SCZ and PD.

Table 4: Shared Molecular Mechanisms in SCZ and PD

Figure 1: Neuroinflammation–Oxidative Stress–Mitochondrial Dysfunction Crosstalk

8. Translational Perspectives for Multi-Target Drug Development

Current pharmacotherapy for schizophrenia and Parkinson’s disease remains largely symptomatic and does not adequately address the underlying neurodegenerative processes. Antipsychotic drugs primarily target dopamine D2 receptors to reduce positive symptoms of schizophrenia but have limited efficacy on negative and cognitive symptoms and are associated with significant adverse effects, including extrapyramidal symptoms and metabolic disturbances (Leucht et al., 2013). Similarly, dopaminergic therapies such as levodopa in Parkinson’s disease provide symptomatic relief of motor symptoms but do not halt neurodegeneration and may lead to long-term complications such as motor fluctuations and dyskinesias. These limitations highlight the urgent need for disease-modifying strategies that target multiple pathological pathways simultaneously.

Multi-target drug design approaches have emerged as a promising strategy to address the complexity of neuropsychiatric and neurodegenerative disorders. Hybrid molecules that combine two or more pharmacophores within a single compound can simultaneously modulate multiple targets, such as dopamine receptors, glutamate receptors, and inflammatory pathways. Polypharmacology-based drug discovery aims to design or identify compounds that interact with multiple biological targets within disease-relevant networks, thereby improving therapeutic efficacy and reducing resistance. Combination therapy using drugs with complementary mechanisms of action is also being explored to simultaneously target neurotransmitter imbalance, oxidative stress, and neuroinflammation.

Natural products and phytopharmaceuticals have gained considerable attention due to their multi-target biological activities and favorable safety profiles. Curcumin exhibits anti-inflammatory, antioxidant, and anti-aggregatory properties through inhibition of NF-κB signaling and modulation of oxidative stress pathways. Resveratrol activates sirtuin signaling pathways and enhances mitochondrial function while reducing neuroinflammation. Quercetin acts as a potent antioxidant and modulates signaling pathways involved in apoptosis and inflammation. Cannabinoid-derived compounds have demonstrated neuroprotective effects through modulation of neurotransmitter release, immune responses, and synaptic plasticity. These natural compounds are particularly attractive for multi-target therapeutic development due to their pleiotropic mechanisms of action.

Nanotechnology-based therapeutic systems offer significant advantages for overcoming pharmacokinetic limitations associated with central nervous system drug delivery. Lipid nanoparticles and polymeric nanoparticles can enhance drug stability, bioavailability, and controlled release profiles. Targeted nanocarriers can be engineered to cross the blood–brain barrier (BBB) and deliver therapeutic agents directly to affected brain regions, improving efficacy while reducing systemic toxicity. BBB-targeted nanoformulations incorporating ligands for receptor-mediated transport systems represent a particularly promising strategy for CNS drug delivery. Controlled drug delivery systems also enable sustained release of neuroprotective agents, improving therapeutic outcomes in chronic neurodegenerative conditions.

Artificial intelligence (AI) and computational drug discovery methods are increasingly being integrated into neuropharmacological research. Machine learning algorithms can be used for target prediction, drug repurposing, and identification of disease-associated molecular signatures. Molecular docking and network pharmacology approaches facilitate identification of multi-target interactions between compounds and disease-related proteins. AI-driven models also enable integration of multi-omics data for precision medicine applications, allowing for patient-specific therapeutic strategies based on molecular profiling (Vamathevan et al., 2019).

Biomarker-guided precision therapeutics represents an emerging paradigm in the treatment of SCZ and PD. Neuroinflammatory biomarkers such as IL-6, TNF-α, and CRP provide insights into immune activation status. Oxidative stress markers including glutathione levels, malondialdehyde, and 8-OHdG reflect redox imbalance and cellular injury. Imaging biomarkers such as PET and MRI-based measures of brain connectivity and neuroinflammation enable non-invasive assessment of disease progression. Genomic biomarkers associated with mitochondrial function, synaptic proteins, and immune signaling pathways further enhance diagnostic precision and therapeutic stratification.

Collectively, these translational approaches highlight a shift from single-target symptomatic treatment toward integrated multi-target and precision medicine strategies. By addressing the interconnected pathological networks underlying schizophrenia and Parkinson’s disease, future therapies may achieve disease modification rather than symptom control, ultimately improving long-term neurological and psychiatric outcomes.

Table 5: Emerging Multi-Target Therapeutics Under Investigation